Hit enter to search or ESC to close
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
Investors Menu
Overview
News Releases
Events
Stock Information
Quote
Interactive Chart
Corporate Governance
Documents & Charters
Board Committees
Financial Information
Snapshot
SEC Filings
Analyst Coverage
Key Ratios
Investor Resources
Contact IR
FAQs
Investor Alerts
RSS
News Releases
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Investor Alerts
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Sep 19, 2022
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Sep 14, 2022
IDEAYA Announces Pricing of Public Offering of Common Stock
Sep 14, 2022
IDEAYA Announces Proposed Public Offering of Common Stock
Sep 11, 2022
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
Sep 6, 2022
IDEAYA Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma
Aug 30, 2022
IDEAYA Biosciences to Participate in Investor Conferences in September 2022
Aug 29, 2022
IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-in-Class Pol Theta Helicase Inhibitor Development Candidate
Aug 15, 2022
IDEAYA Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 27, 2022
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
Jul 27, 2022
IDEAYA Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
15
»
Company
Science
Pipeline
Newsroom
Investors
Careers
Contact